Variations of Subunit   of the Mycobacterium tuberculosis F1Fo ATP Synthase and a Novel Model for Mechanism of Action of the Tuberculosis Drug TMC207 (original) (raw)

Mycobacterium tuberculosis poses a critical global health challenge, with a high burden of drug-resistant strains. TMC207, a diarylquinoline, shows promise as a new drug targeting ATP synthesis in M. tuberculosis, effectively killing both replicating and dormant bacteria. This work provides insights into the variations of the ATP synthase subunit structure and proposes a model elucidating the mechanism of action of TMC207, highlighting its potential for treating multidrug-resistant tuberculosis.